title: Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
authors.forename: Uta
authors.initials: U
authors.lastname: Herden
authors.forename: Lutz
authors.initials: L
authors.lastname: Fischer
authors.forename: Hansjörg
authors.initials: H
authors.lastname: Schäfer
authors.forename: Björn
authors.initials: B
authors.lastname: Nashan
authors.forename: Volker
authors.initials: V
authors.lastname: von Baehr
authors.forename: Martina
authors.initials: M
authors.lastname: Sterneck
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000601:surgery*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D006526:Hepatitis C / Q000601:surgery*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery*; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D001663:Bilirubin